103 studies found for:    "Sclerosis" AND (woman OR women OR female)
Show Display Options
RSS Create an RSS feed from your search for:
"Sclerosis" AND (woman OR women OR female)
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS)
Conditions: Urinary Incontinence;;   Multiple Sclerosis
Intervention: Behavioral: Paula method
2 Recruiting Teriflunomide Male Transmission Study
Condition: Multiple Sclerosis
Intervention:
3 Recruiting Genes and Environment in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
4 Recruiting Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
Conditions: Multiple Sclerosis;   Alzheimer's Disease
Intervention: Drug: [F-18]PBR06
5 Recruiting A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Conditions: Menopause;   Multiple Sclerosis
Interventions: Drug: Tissue Selective Estrogen Complex;   Drug: Placebo
6 Completed Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
7 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
8 Recruiting A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Condition: Progressive Multiple Sclerosis
Interventions: Drug: GZ402668;   Drug: Placebo;   Drug: Acyclovir
9 Completed A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Condition: Progressive Multiple Sclerosis
Interventions: Drug: GZ402668;   Drug: placebo;   Drug: acyclovir
10 Completed Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training
Conditions: Multiple Sclerosis;   Aquatic;   Exercise
Interventions: Behavioral: Exercise;   Behavioral: Control
11 Completed Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Condition: Systemic Sclerosis
Intervention: Drug: Cialis
12 Completed Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: firategrast
13 Completed Treatment of Multiple Sclerosis With Copaxone and Albuterol
Conditions: Autoimmune Diseases;   Multiple Sclerosis
Interventions: Drug: Glatiramer acetate;   Drug: Albuterol;   Drug: Albuterol placebo
14 Completed AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
Conditions: Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
15 Terminated Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
Condition: Multiple Sclerosis (MS) - Relapsing-remitting
Intervention: Biological: sirolimus
16 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
17 Unknown  Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
18 Completed Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: firategrast (SB683699)
19 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
20 Withdrawn Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Condition: Multiple Sclerosis
Interventions: Drug: Rebif (IFN β-1a subcutaneous three times per week);   Drug: Tecifdera (dimethyl fumarate)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.